Trials / Completed
CompletedNCT03183024
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jonathan A. Bernstein, MD · Academic / Other
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine the efficacy of benralizumab when compared to placebo in patients with chronic hives that do not respond to antihistamine treatment
Detailed description
Subjects with chronic hives that do not respond to antihistamine treatment and have hives of unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the run-in phase will receive 3 doses of study medication. The study also involved blood draws and a punch biopsy of a hive
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | benralizumab | open-label treatment |
| BIOLOGICAL | placebo | sterile water to mimic benralizumab |
Timeline
- Start date
- 2017-09-12
- Primary completion
- 2018-11-06
- Completion
- 2018-11-06
- First posted
- 2017-06-09
- Last updated
- 2019-07-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03183024. Inclusion in this directory is not an endorsement.